Synteract scores contract for brain cancer trial

By Kirsty Barnes

- Last updated on GMT

Related tags Clinical trial

California-based Synteract has scored a clinical trial management
contract from Northwest Biotherapeutics to bring one of the world's
first personalised medicines into a late stage clinical trial.

Under the contract, Synteract will perform full service management of a pivotal Phase II trial of its new drug to treat glioblastoma multiforme - the most lethal form of brain cancer.

The terms of the contract were not disclosed.

Currently there are only two Food and Drug Administration (FDA)-approved therapies for brain cancer and the prognosis for patients with this disease is particularly poor.

Northwest's new trial drug, DCVax-Brain is a personalised therapeutic cancer vaccine using the patient's own dendritic cells (immune cells) with the patient's own tumour biomarkers (antigens).

"This Phase II trial has the potential to become one of the first cancer immunotherapies, an entirely new class of treatment for brain cancer,"​ said Alton Boynton president of Northwest Biotherapeutics.

Two Phase I trials have already been carried out on the drug at out at UCLA in California, with the company heralding the results as "striking."

Data from the first trial demonstrated that patient survival on the drug was more than double that of patients receiving either of the two FDA-approved drugs.

The second trial, which has been ongoing since 2002, has six out of ten patients still surviving so far, with median survival not yet reached - five of which continue to be cancer-free, with no recurrence.

Survival times in this trial now range up to 44.4 months and are still continuing, said the firm.

Related topics Clinical Development Phase I-II

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more